MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$2.05 +2.02%

+$0.08 today

Market cap
$131.01M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.57M

Average 0.98M

MGNX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

MacroGenics, Inc.NASDAQ: MGNX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$30.2M, compared with -$39.17M a year earlier. Trailing-twelve-month EBITDA was -$50.64M.

Context

  • EBITDA amounted to 39.9% of revenue in FY2025, up 1.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$105.61M (-77.2%) for the fiscal year ending Dec 2026, a slowdown from the -3.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30.2M-237.2% QoQ
Last fiscal yearDec 2025
-$59.61M-3.9% YoY
LTMMar 2026
-$50.64M-7.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.9%+100.4%+77.5 pp
1 year-3.9%-77.2%-73.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(59.61M) USD
Year-over-year change
-3.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.0% is the 6th highest of 11, against a peer median of -8.4%.
  • EBITDA amounts to 32.2% of revenue for MGNX, versus a peer median of 13207.8%.
MGNX Competitors
EBITDA for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M USD+1391.3%——
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.1M USD-18.3%—265.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M USD+7.8%—337.0%
CLNNClene Inc.LTM Mar 2026-$29.2M USD-21.6%—21792.5%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M USD-45.5%——
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.78M USD-490.7%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$130.98M USD+37.9%——
Peer median (excluding MGNX) —-8.4%—13207.8%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$2.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.